Retatrutide Side Effects: An Honest Breakdown of the Phase 2 Data
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.
Key Takeaways
- The most common retatrutide side effects in Phase 2 were gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are consistent with the GLP-1 class.
- GI side effects were dose-dependent. Higher doses produced more adverse events.
- A distinct signal not seen in GLP-1/GIP dual agonists: dysesthesia (abnormal skin sensations). Phase 2 data reported rates of 8.8% at lower doses and 20.9% at higher doses according to the sponsor.
- Discontinuation rates due to adverse events were higher than placebo but comparable to other drugs in this class.
- No new concerning cardiac, hepatic, or renal safety signals emerged from Phase 2 data.
- Phase 3 TRIUMPH trials will provide the definitive safety profile across thousands of patients.
Why the Triple Agonist Mechanism Changes the Safety Picture
The retatrutide side effects reported in Phase 2 trials follow patterns seen with other GLP-1 drugs, but with important differences. For a broader look at this compound, see our retatrutide guide. Most GLP-1 receptor agonists on the market, including semaglutide and tirzepatide, activate one or two receptor types. Semaglutide is a GLP-1 agonist. Tirzepatide adds GIP receptor activation.
Retatrutide adds a third: glucagon receptor agonism.
This matters for the side effect profile in two ways.
First, GLP-1 and GIP receptor activation produce the familiar GI effects: nausea, slowed gastric emptying, early satiety, and occasional vomiting. These mechanisms are shared with the entire class.
Second, glucagon receptor activation produces different metabolic effects. Glucagon raises blood glucose, increases energy expenditure, and promotes fat oxidation in the liver. In the context of simultaneous GLP-1 and GIP activation, the blood glucose increase from glucagon appears to be buffered. But the metabolic and potentially neurological effects of glucagon receptor agonism introduce tolerability factors that do not exist with dual agonists.
The dysesthesia signal, which has not been reported at clinically notable rates in semaglutide or tirzepatide trials, is the clearest example of a side effect profile that may be partially driven by the glucagon component.
GI Side Effects: What Phase 2 Showed
The primary Phase 2 efficacy and safety data is from Jastreboff et al., published in the New England Journal of Medicine (PMID 37366315). The trial enrolled 338 adults across dose groups ranging from 1mg to 12mg weekly.
Nausea
Nausea was the most frequently reported adverse event. Rates were dose-dependent.
In the highest dose groups (8mg and 12mg), nausea was reported by a substantial portion of participants. The 12mg group showed nausea rates comparable to the highest semaglutide dose groups in STEP trials.
The pattern is consistent with GLP-1 agonism: nausea is most common during dose escalation and tends to decrease over time as the body adapts. Most nausea in the trial was described as mild to moderate in severity.
Vomiting
Vomiting rates followed the same dose-response pattern as nausea. Higher doses produced higher vomiting rates. Again, this mirrors the GLP-1 class profile.
Diarrhea
Diarrhea was reported across dose groups and was not as strongly dose-dependent as nausea and vomiting. Rates were generally similar to those reported with tirzepatide in the SURMOUNT-1 trial.
Constipation
Constipation was also reported, particularly in mid-to-high dose groups. Slowed gastrointestinal motility is a known GLP-1 receptor effect. Retatrutide's GLP-1 component would be expected to contribute to this.
Decreased appetite
Decreased appetite was reported as an adverse event by some participants, reflecting the drug's mechanism. The distinction between desired pharmacological effect and adverse experience is context-dependent for this signal.
The Dysesthesia Signal: What We Know
Dysesthesia refers to abnormal, often unpleasant skin sensations. This can include tingling, burning, crawling sensations, or heightened sensitivity to touch. It is not the same as neuropathy, though both involve altered sensory perception.
In the Phase 2 retatrutide data, the sponsor reported dysesthesia rates of approximately 8.8% at lower doses and 20.9% at higher doses. These rates are notable because:
- Dysesthesia is not a commonly reported adverse event in semaglutide or tirzepatide Phase 2 or Phase 3 data at these rates.
- The dose-response relationship suggests a pharmacological mechanism rather than coincidental reporting.
- The mechanism is not fully understood. Glucagon receptors are expressed in neural tissues. Glucagon receptor agonism may contribute to sensory effects.
It is important to be precise about what "according to the sponsor" means in this context. Sponsor-reported data from Phase 2 is the starting point for characterization, not the final word. Phase 3 will include much larger populations, longer observation periods, and more systematic adverse event collection. The dysesthesia signal may become clearer, may diminish in magnitude, or may produce additional mechanistic understanding.
For people considering retatrutide: this is a real signal that does not exist in the same form in other GLP-1 class drugs. It should be part of an informed risk-benefit conversation with a physician.
Comparison to Tirzepatide Side Effects
Tirzepatide (Zepbound/Mounjaro) is the most direct comparator for retatrutide. Both are Eli Lilly compounds. Both activate GIP and GLP-1 receptors. Retatrutide adds glucagon receptor agonism.
| Adverse Event | Tirzepatide (SURMOUNT-1) | Retatrutide (Phase 2, 12mg) |
|---|---|---|
| Nausea | ~30-33% | Comparable or slightly higher |
| Diarrhea | ~17-23% | Comparable |
| Vomiting | ~8-10% | Comparable or slightly higher |
| Constipation | ~11-12% | Comparable |
| Dysesthesia | Not prominently reported | ~8.8-20.9% (sponsor-reported) |
| Discontinuation (AE-related) | ~4-6% | Higher at highest doses |
The GI profile is broadly comparable between the two compounds. The dysesthesia signal is the most notable difference. Whether Phase 3 data confirms this distinction at scale is a key question.
It should also be noted that tirzepatide's GI tolerability in Phase 2 was similar to semaglutide. Phase 3 with larger populations and longer durations generally shows a slightly more complete picture of low-frequency events.
Comparison to Semaglutide Side Effects
For reference, semaglutide (Wegovy/Ozempic) at 2.4mg weekly showed the following in STEP-1 (PMID 33567185):
- Nausea: ~44% (vs ~7% placebo)
- Diarrhea: ~30%
- Vomiting: ~24%
- Constipation: ~24%
- Discontinuation due to GI AEs: ~4.5%
Retatrutide's GI profile at comparable weight loss doses appears broadly similar to semaglutide's. Whether it is better or worse will require head-to-head Phase 3 data that does not yet exist.
Discontinuation Rates
In Phase 2, the proportion of participants discontinuing due to adverse events was higher in higher dose groups compared to lower dose groups and placebo. This is consistent with the dose-response relationship across GI and other adverse events.
The discontinuation rate in the highest dose groups exceeded the rates seen in tirzepatide Phase 3 trials. Whether this holds in Phase 3 with larger populations and gradual dose escalation protocols depends on the escalation schedule used and patient selection.
Dose escalation speed matters significantly for GI tolerability. Slower escalation to target dose tends to reduce GI adverse event rates. The TRIUMPH trials will use structured escalation protocols.
Managing Side Effects: What Phase 2 Participants Experienced
The clinical trial context provided several observations about adverse event management:
Timing of GI symptoms: Most nausea occurred during dose escalation phases and decreased after reaching stable dosing. This is the same pattern seen with semaglutide and tirzepatide.
Dose reduction: Some participants received dose reductions in response to intolerable side effects. Phase 3 protocols will have defined procedures for this.
Concurrent medications: Trial participants were typically advised on dietary modifications (smaller meals, avoiding high-fat foods) as standard GI management during dose escalation.
Resolution: Most GI events were transient, not requiring discontinuation. Serious GI adverse events were uncommon.
For dysesthesia specifically, Phase 2 did not produce extensive detail on onset, duration, severity, or resolution. Phase 3 data will provide a clearer picture.
Serious Adverse Events and Safety Monitoring
Phase 2 data did not reveal concerning signals in several categories that require close monitoring for this drug class:
Pancreatitis: GLP-1 receptor agonists carry a class label regarding pancreatitis risk. No clinically significant increase was reported in Phase 2 retatrutide data.
Thyroid: GLP-1 agonists carry a medullary thyroid carcinoma warning (based on rodent data). Retatrutide Phase 2 data did not produce a human thyroid safety signal, consistent with the class.
Cardiovascular: No adverse cardiovascular signal was detected. TRIUMPH-6 is specifically designed to generate cardiovascular outcomes data.
Hepatic and renal: No notable hepatic or renal safety signals were observed in Phase 2.
Cancer: A preclinical mouse model study examined retatrutide's potential effects on tumor biology (PMID 40094000). This was mouse model data only. There is no human evidence regarding cancer risk from retatrutide, and drawing clinical conclusions from preclinical data is not appropriate.
What Phase 3 Will Tell Us
Phase 2 enrolled 338 participants over 48 weeks. TRIUMPH Phase 3 trials enroll thousands of participants over longer durations.
Scale matters for safety for several reasons:
- Low-frequency adverse events (occurring in 1-2% of patients) require large populations to detect reliably.
- Longer observation periods surface delayed-onset effects.
- More diverse patient populations (different comorbidities, age ranges, concurrent medications) reveal interaction effects not visible in tightly controlled Phase 2 populations.
The full retatrutide safety profile will not be known until Phase 3 data is published. Phase 2 data is informative but not definitive.
Frequently Asked Questions {#faq}
What are the most common side effects of retatrutide?
In Phase 2 clinical trial data, the most common adverse events were nausea, diarrhea, vomiting, and constipation. These are consistent with the GLP-1 receptor agonist drug class. They were most frequent during dose escalation and tended to decrease at stable doses.
Is retatrutide safe?
Retatrutide is an investigational compound still in Phase 3 trials. The complete safety profile is not yet known. Phase 2 data showed a GI side effect profile broadly similar to tirzepatide, with the addition of a dysesthesia signal not prominently seen in other GLP-1 class drugs. "Safe" as an absolute description is not accurate for any drug, approved or investigational.
What is dysesthesia and why does retatrutide cause it?
Dysesthesia is an abnormal skin sensation, sometimes described as tingling, burning, or crawling. Phase 2 sponsor-reported data showed rates of approximately 8.8% at lower doses and 20.9% at higher doses. The mechanism is not fully characterized. Glucagon receptors are expressed in neural tissue, and the glucagon receptor agonism component of retatrutide may contribute. Phase 3 will provide more data on this signal.
How does retatrutide compare to tirzepatide for side effects?
The GI side effect profiles are broadly comparable. Both produce nausea, diarrhea, vomiting, and constipation in dose-dependent patterns. The notable difference is the dysesthesia signal in retatrutide, which does not appear at comparable rates in tirzepatide Phase 3 data. Whether this translates to a clinically meaningful difference in tolerability will depend on Phase 3 data.
Will nausea go away over time?
Based on Phase 2 observations and the broader GLP-1 class experience, most nausea associated with retatrutide occurred during dose escalation and diminished at stable dosing. This pattern is consistent with semaglutide and tirzepatide. Individual responses vary significantly.
Are there any serious side effects from retatrutide?
Phase 2 data did not reveal significant pancreatitis, cardiovascular, thyroid, hepatic, or renal safety signals. The drug carries the standard GLP-1 class monitoring considerations for pancreatitis and thyroid. Definitive serious adverse event characterization requires Phase 3 scale. Anyone in a clinical trial is monitored closely for these signals.
Does retatrutide cause heart problems?
Phase 2 data did not show a cardiovascular adverse signal. TRIUMPH-6 is specifically designed as a cardiovascular outcomes trial and will provide the most rigorous data on this question. The compound's weight loss and metabolic effects are theorized to be cardiovascular-favorable, but this requires dedicated trial data to confirm.
What are the side effects of gray market retatrutide?
Compounds sold as retatrutide through gray market research chemical vendors are not the same as Eli Lilly's investigational compound. They are not manufactured under pharmaceutical-grade conditions, may have incorrect concentrations, and may contain contaminants. The side effect profile of gray market research compounds is unknown and unverifiable. We do not endorse their use.
Related Reading
- Retatrutide Complete Guide - Full mechanism overview, Phase 2 and Phase 3 data, and what makes this compound different from tirzepatide
- How to Get Retatrutide - Current access pathways: clinical trials, research compounds, and what post-approval looks like
- Retatrutide Cost: What to Expect - Projected pricing and insurance coverage landscape post-approval
- Retatrutide Clinical Trials 2026 - All 7 TRIUMPH Phase 3 trials, what each is measuring, and timeline expectations
- GLP-1 Peptides: Complete Guide - Full class overview and how GLP-1 receptor agonism drives both efficacy and GI side effects
Medical Disclaimer
The information in this article is provided for educational purposes only. Peptide Nerds is not a medical practice and does not provide medical advice, diagnosis, or treatment recommendations. Side effect data described in this article is drawn from published Phase 2 clinical trial research. Retatrutide has not received FDA approval. The safety profile described here is preliminary and will be further characterized through ongoing Phase 3 TRIUMPH trials. Nothing in this article should be interpreted as a minimization of side effect risks or as a recommendation to use retatrutide or any unapproved compound. Always consult a licensed physician before making decisions about medications or health protocols.
Sources
- Jastreboff AM et al. (2023). Retatrutide Phase 2 Safety and Efficacy. NEJM. PMID 37366315. - Primary Phase 2 adverse event data including GI rates and dysesthesia signal
- Heymsfield SB et al. (2022). Retatrutide Phase 1 Dose Escalation. PMID 36354040. - Initial Phase 1 safety characterization
- Ludvik B et al. (2023). 36-Week Data. PMID 37385280. - Extended safety and efficacy observations
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM, 2022. SURMOUNT-1 trial data on tirzepatide side effect rates. PMID 35658024.
- Wilding JPH et al. (2021). Semaglutide STEP-1. NEJM. PMID 33567185. - Semaglutide Phase 3 side effect comparison reference
- Müller TD et al. (2023). MASH Phase 2 Data. PMID 38858523. - Liver-specific Phase 2 safety and efficacy data
- Frías JP et al. (2024). TRIUMPH Program Design. PMID 41090431. - Phase 3 program overview including safety monitoring framework
- Preclinical Cancer Study. PMID 40094000. - Mouse model preclinical data, no human evidence
Schema Markup
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"@id": "https://peptidenerds.com/#organization",
"name": "Peptide Nerds",
"url": "https://peptidenerds.com",
"logo": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/logo.png"
}
},
{
"@type": "Article",
"@id": "https://peptidenerds.com/blog/retatrutide-side-effects-what-to-expect/#article",
"headline": "Retatrutide Side Effects: An Honest Breakdown of the Phase 2 Data",
"description": "Retatrutide side effects from Phase 2 data: GI rates by dose, dysesthesia signal, comparison to tirzepatide, and what the triple agonist mechanism changes.",
"datePublished": "2026-03-11",
"dateModified": "2026-03-11",
"author": {
"@type": "Organization",
"name": "Peptide Nerds Editorial Team"
},
"publisher": {
"@id": "https://peptidenerds.com/#organization"
},
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://peptidenerds.com/blog/retatrutide-side-effects-what-to-expect/"
},
"image": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/retatrutide-side-effects-what-to-expect.jpg"
}
},
{
"@type": "FAQPage",
"@id": "https://peptidenerds.com/blog/retatrutide-side-effects-what-to-expect/#faq",
"mainEntity": [
{
"@type": "Question",
"name": "What are the most common side effects of retatrutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "In Phase 2 clinical trial data, the most common adverse events were nausea, diarrhea, vomiting, and constipation. These are consistent with the GLP-1 receptor agonist drug class and were most frequent during dose escalation."
}
},
{
"@type": "Question",
"name": "Is retatrutide safe?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Retatrutide is an investigational compound still in Phase 3 trials. The complete safety profile is not yet known. Phase 2 data showed a GI side effect profile broadly similar to tirzepatide, with the addition of a dysesthesia signal not prominently seen in other GLP-1 class drugs."
}
},
{
"@type": "Question",
"name": "What is dysesthesia and why does retatrutide cause it?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Dysesthesia is an abnormal skin sensation, sometimes described as tingling, burning, or crawling. Phase 2 sponsor-reported data showed rates of approximately 8.8% at lower doses and 20.9% at higher doses. The mechanism is not fully characterized, but glucagon receptor agonism may contribute as glucagon receptors are expressed in neural tissue."
}
},
{
"@type": "Question",
"name": "How does retatrutide compare to tirzepatide for side effects?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The GI side effect profiles are broadly comparable. Both produce nausea, diarrhea, vomiting, and constipation in dose-dependent patterns. The notable difference is the dysesthesia signal in retatrutide, which does not appear at comparable rates in tirzepatide Phase 3 data."
}
},
{
"@type": "Question",
"name": "Will nausea go away over time with retatrutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Based on Phase 2 observations and the broader GLP-1 class experience, most nausea occurred during dose escalation and diminished at stable dosing. This pattern is consistent with semaglutide and tirzepatide. Individual responses vary significantly."
}
},
{
"@type": "Question",
"name": "Are there any serious side effects from retatrutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Phase 2 data did not reveal significant pancreatitis, cardiovascular, thyroid, hepatic, or renal safety signals. The compound carries standard GLP-1 class monitoring considerations. Definitive serious adverse event characterization requires Phase 3 scale data."
}
},
{
"@type": "Question",
"name": "Does retatrutide cause heart problems?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Phase 2 data did not show a cardiovascular adverse signal. TRIUMPH-6 is specifically designed as a cardiovascular outcomes trial. The compound's weight loss and metabolic effects are theorized to be cardiovascular-favorable, but this requires dedicated trial data to confirm."
}
},
{
"@type": "Question",
"name": "What are the side effects of gray market retatrutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Compounds sold as retatrutide through gray market research chemical vendors are not manufactured under pharmaceutical-grade conditions, may have incorrect concentrations, and may contain contaminants. The side effect profile of such products is unknown and unverifiable."
}
}
]
}
]
}
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.